Literature DB >> 8832586

Differences in acetylcholine- and bradykinin-induced vasorelaxation of the mesenteric vascular bed in spontaneously hypertensive rats of different ages.

K J Wirth1, W Linz, G Wiemer, B A Schölkens.   

Abstract

The present study examined whether alterations of endothelium-dependent vasorelaxation in spontaneously hypertensive rats (SHR) in response to the endothelium-dependent vasodilators acetylcholine and bradykinin ran parallel. We tried to find out the age at which endothelium-dependent vasorelaxation in response to each agonist became impaired and compared three different groups of SHR aged 7, 21 and 51 weeks. To be able to separate hypertension-induced alterations from age-dependent changes age-matched normotensive Wistar rats were included. Endothelium-dependent vasorelaxation was studied in the mesenteric vascular bed precontracted with noradrenaline, a typical resistance vessel, which showed relaxation to both acetylcholine and bradykinin, and the precontracted thoracic aorta, which only responded to acetylcholine. There were major differences in the agonist-dependent vasorelaxation between bradykinin and acetylcholine in SHR as a function of age. A surprising finding was that acetylcholine-induced relaxation was preserved, even slightly improved not only in young SHR (7 weeks) with developing hypertension but also in adult SHR (21 weeks) with established hypertension, which can be interpreted as a compensatory mechanism. As expected, in old SHR (51 weeks) acetylcholine-induced vasorelaxation was impaired as a consequence of the detrimental effects of long-term hypertension on endothelium. The parallel changes observed with acetylcholine in the mesenteric vascular bed and thoracic aorta provided mutual confirmation. In clear contrast to acetylcholine bradykinin-induced vasorelaxation was already imparied in young SHR with developing hypertension suggesting that bradykinin-induced vasorelaxation is either much more sensitive to detrimental effects of (even slightly) increased blood pressure or, more likely, that there is a basic deficiency in the action of bradykinin in SHR. Thus, our study allows to conclude that impairment of acetylcholine-induced endothelium-dependent vasorelaxation in the mesenteric vascular bed of SHR is a secondary phenomenon developing as a consequence of long-term hypertension while the impaired bradykinin-induced vasorelaxation seems to be a primary phenomenon that could be closely related to the development of hypertension.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8832586     DOI: 10.1007/bf00168704

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway.

Authors:  D Diederich; Z H Yang; F R Bühler; T F Lüscher
Journal:  Am J Physiol       Date:  1990-02

2.  In vitro perfusion studies of resistance artery function in genetic hypertension.

Authors:  B J Falloon; S J Bund; J R Tulip; A M Heagerty
Journal:  Hypertension       Date:  1993-10       Impact factor: 10.190

3.  Contribution of bradykinin to maintenance of blood pressure and renal blood flow in anaesthetized spontaneously hypertensive rats.

Authors:  M Seino; K Abe; N Nushiro; K Omata; Y Kasai; K Yoshinaga
Journal:  J Hypertens Suppl       Date:  1988-12

4.  Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models.

Authors:  G Bao; P Gohlke; T Unger
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

5.  The vasodilatory effect of endogenous nitric oxide is a major counter-regulatory mechanism in the spontaneously hypertensive rat.

Authors:  J F Arnal; T Battle; J Ménard; J B Michel
Journal:  J Hypertens       Date:  1993-09       Impact factor: 4.844

6.  Decreased endothelium-dependent relaxation in New Zealand genetic hypertensive rats.

Authors:  R J Winquist; P B Bunting; E P Baskin; A A Wallace
Journal:  J Hypertens       Date:  1984-10       Impact factor: 4.844

7.  Enhanced release of endothelium-derived relaxing factor in mineralocorticoid hypertension.

Authors:  C S Bockman; W B Jeffries; W A Pettinger; P W Abel
Journal:  Hypertension       Date:  1992-09       Impact factor: 10.190

8.  Indomethacin improves the impaired endothelium-dependent relaxations in small mesenteric arteries of the spontaneously hypertensive rat.

Authors:  T F Lüscher; L L Aarhus; P M Vanhoutte
Journal:  Am J Hypertens       Date:  1990-01       Impact factor: 2.689

9.  Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat.

Authors:  T F Lüscher; P M Vanhoutte
Journal:  Hypertension       Date:  1986-04       Impact factor: 10.190

Review 10.  The endothelium in hypertension: bystander, target or mediator?

Authors:  T F Lüscher
Journal:  J Hypertens Suppl       Date:  1994-12
View more
  4 in total

1.  Brain injury after intracerebral hemorrhage in spontaneously hypertensive rats.

Authors:  Gang Wu; Xuhui Bao; Guohua Xi; Richard F Keep; B Gregory Thompson; Ya Hua
Journal:  J Neurosurg       Date:  2011-02-04       Impact factor: 5.115

2.  Effect of nitro-L-arginine on electrical and mechanical responses to acetylcholine in the superior mesenteric artery from stroke-prone hypertensive rat.

Authors:  P Ghisdal; T Godfraind; N Morel
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

3.  Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease.

Authors:  Leanid Luksha; Peter Stenvinkel; Folke Hammarqvist; Juan Jesús Carrero; Sandra T Davidge; Karolina Kublickiene
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

4.  Increased Vascular Contractility in Hypertension Results From Impaired Endothelial Calcium Signaling.

Authors:  Calum Wilson; Xun Zhang; Charlotte Buckley; Helen R Heathcote; Matthew D Lee; John G McCarron
Journal:  Hypertension       Date:  2019-09-23       Impact factor: 10.190

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.